Exploratory, Participatory and Iterative Assessment of Value: A Response to Recent Commentaries

Document Type: Correspondence

Authors

1 Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

2 Department for Operating Rooms, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

3 Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands

4 Department for Health Evidence, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, The Netherlands

Keywords


We were deeply honoured that so many reputable scholars read our article and took the effort to write no less than eight thoughtful and interesting commentaries.1-8 Writing the original paper was sometimes a struggle, because it was an unconventional paper. However, we felt a strong urge to make these assessments – that are often confidential and not publicly available – public, and share our experiences to advance this important and timely field of research... (Read more)

 

  1. Drummond MF. Modeling in early stages of technology development: is an iterative approach needed? Comment on “Problems and promises of health technologies: the role of early health economic modeling.” Int J Health Policy Manag.  2020, 9(6), 260–262.  doi:10.15171/ijhpm.2019.118
  2. Federici C, Torbica A. Expanding the role of early health economic modelling in evaluation of health technologies: Comment on “Problems and promises of health technologies: the role of early health economic modeling.” Int J Health Policy Manag. 2020; In Press. doi:10.15171/ijhpm.2020.18
  3. Kim H, Goodall S, Liew D. The potential for early health economic modelling in health technology assessment and reimbursement decision-making: Comment on “Problems and promises of health technologies: the role of early health economic modeling.” Int J Health Policy Manag. 2020; In Press. doi:10.15171/ijhpm.2020.17
  4. Lehoux P, Silva H. Transforming Disciplinary Traditions; Comment on “Problems and promises of health technologies: the role of early health economic modeling.” Int J Health Policy Manag. 2020; In Press.  doi:10.15171/ijhpm.2019.130
  5. Love-Koh J. How useful are early economic models? Comment on “Problems and promises of health technologies: the role of early health economic modelling.” Int J Health Policy Manag. 2020;9(5):215-217. doi:10.15171/ijhpm.2019.119
  6. Partington A, Karnon J. It’s not the model, it’s the way you use it: exploratory early health economics amid complexity: Comment on “Problems and promises of health technologies: the role of early health economic modelling.” Int J Health Policy Manag. 2020; In Press.  doi:10.15171/ijhpm.2020.04
  7. Teljeur C, Ryan M. Early health economic modelling – optimizing development for medical device developers? Comment on “Problems and promises of health technologies: the role of early health economic modeling.” Int J Health Policy Manag. 2020; In Press.  doi:10.15171/ijhpm.2019.136
  8. Zawadzki NK, Hay JW. Characterizing the validity and real-world utility of health technology assessments in healthcare: future directions; Comment on “Problems and promises of health technologies: the role of early health economic modelling.” Int J Health Policy Manag. 2020; In Press. doi:10.15171/ijhpm.2019.132
  9. Briggs AH, Weinstein MC, Fenwick EA, et al. Model parameter estimation and uncertainty: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--6. Value Health. 2012;15(6):835-842. doi:10.1016/j.jval.2012.04.014
  10. Kwakkel JH, Pruyt E. Exploratory modeling and analysis, an approach for model-based foresight under deep uncertainty. Technological Forecasting and Social Change. 2013;80(3):419-431. doi:10.1016/j.techfore.2012.10.005
  11. Kwakkel JH, Haasnoot M. Supporting DMDU: A taxonomy of approaches and tools. In: Marchau VAWJ, Walker WE, Bloemen PJTM, Popper SW, eds. Decision Making Under Deep Uncertainty: From Theory to Practice. Switzerland: Springer Nature 2019.
  12. Pouwels X, Grutters JPC, Bindels J, Ramaekers BLT, Joore MA. Uncertainty and coverage with evidence development: does practice meet theory? Value Health. 2019;22(7):799-807. doi:10.1016/j.jval.2018.11.010
  13. Grimm SE, Pouwels X, Ramaekers BLT, et al. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) tool for assessing uncertainties in health economic decision models. Pharmacoeconomics. 2020;38(2):205-216. doi:10.1007/s40273-019-00855-9
  14. Grutters JP, van Asselt MB, Chalkidou K, Joore MA. Healthy decisions: towards uncertainty tolerance in healthcare policy. Pharmacoeconomics. 2015;33(1):1-4. doi:10.1007/s40273-014-0201-7
  15. Kluytmans A, Tummers M, Van der Wilt GJ, Grutters JPC. Early assessment of proof-of-problem to guide health innovation. Value Health. 2019;22(5):601-606.
  16. Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J Health Serv Res Policy. 1997;2(1):26-30. doi:10.1177/135581969700200107
  17. van Bruggen A, Nikolic I, Kwakkel J. Modeling with stakeholders for transformative change. Sustainability. 2019;11(3):825. doi:10.3390/su11030825
  18. Frederix GW, van Hasselt JG, Schellens JH, et al. The impact of structural uncertainty on cost-effectiveness models for adjuvant endocrine breast cancer treatments: the need for disease-specific model standardization and improved guidance. Pharmacoeconomics. 2014;32(1):47-61. doi:10.1007/s40273-013-0106-x